Weizmann scientists are now developing Israeli-invented CAR-T cancer therapy (see here previously) to cure brain diseases such as Alzheimer’s. The team of Israeli and American scientists have modified T cells to recognize and respond to amyloid proteins in the brain. … Continue reading →

Doctors at Israel’s Rabin Medical Center have successfully deployed homegrown CAR-T therapy for multiple myeloma. The treatment was developed and manufactured at the Samueli Integrative Cancer Pioneering Institute. Israel diagnoses roughly 550 new cases of multiple myeloma each year. https://www.jns.org/israeli-breakthrough-a-new-treatment-for-blood-cancer/

Israeli-invented CAR-T immunotherapy, which re-arms T-cells with synthetic receptors to seek and destroy malignant cells, has already changed the outlook for several blood cancers worldwide and is steadily expanding in Israeli hospitals through tightly regulated clinical programs. https://unitedwithisrael.org/israeli-doctors-weaponize-patients-own-immune-cells-to-destroy-aggressive-blood-cancer/

A Weizmann Institute-led international team of researchers has found how bacteria in the gut microbiome affects the body’s response to cancer immunotherapy (see also here previously). Also, patients treated with specific antibiotics had a poor response to CAR-T cancer treatment. … Continue reading →

20-year-old Kalim was sent home from hospital to die in St Petersburg after doctors said they could not treat his acute lymphoblastic leukemia. He immigrated to Israel where five months of CAR-T treatment at Rambam Health Care Campus gave Kalim … Continue reading →

Scientists at Jerusalem’s Hadassah hospital and Bar-Ilan University have developed HBI0101- a CAR-T therapy for multiple myeloma and amyloidosis, benefiting over 90% of patients in trials. Los Angeles-based Immix BioPharma will commercialize HBI0101. https://www.timesofisrael.com/after-demonstrating-57-remission-rate-israeli-immunotherapy-licensed-by-us-firm/ https://haematologica.org/article/view/haematol.2022.281628

Israel’s ImmPACT Bio is developing transformative logic-gate-based CAR-T cell therapies for cancer patients who have exhausted their treatment options. The technology is designed to distinguish cancerous cells from normal cells, thereby eliminating tumors without damaging normal tissues. https://en.globes.co.il/en/article-cancer-therapy-co-immpact-bio-raises-111m-1001399387 https://immpact-bio.com/

The Car-T cancer therapy invented by Israel’s Professor Zelig Eshhar (see here) is curing thousands of blood cancer patients. But the manual effort is hugely expensive. Now Israel’s ADVA Biotechnologies is developing a simpler, automated process. More lives will be … Continue reading →

According to the BBC, the CAR-T cancer therapy, (invented by Professor Zelig Eshhar of Israel’s Weizmann Institute) is curing 40% of UK lymphoma patients who were otherwise untreatable and terminal.  Amazing case stories – but doesn’t mention Israel of course! … Continue reading →

Israel’s Sheba hospital is partnering with Switzerland’s Lonza Group to fast-track production of the CAR-T cancer immunotherapy invented by Israeli scientists. Sheba is the first hospital to trial and refine Lonza’s Cocoon manufacturing platform for growing cells to treat hundreds … Continue reading →